The Oncology Institute Inc TOI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TOI is a good fit for your portfolio.
News
-
The Oncology Institute Announces First Quarter 2024 Earnings Release Date and Conference Call
-
Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute
-
The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California
-
The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024
-
MaxHealth & The Oncology Institute Expand Value-Based Care Partnership
-
The Oncology Institute Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call
-
The Oncology Institute to Participate at Upcoming Investor Conferences
-
Carrum Health and The Oncology Institute Partner on Breast Cancer Treatment Model
Trading Information
- Previous Close Price
- $1.18
- Day Range
- $1.13–1.26
- 52-Week Range
- $0.33–2.66
- Bid/Ask
- $1.00 / $1.16
- Market Cap
- $85.46 Mil
- Volume/Avg
- 79,351 / 113,440
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 1.19%
Company Profile
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Stock Style Box
- Small Value
- Total Number of Employees
- 800
Valuation
|
Metric
|
TOI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.50 |
Price/Sales | 0.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TOI
|
|---|---|
Quick Ratio | 3.62 |
Current Ratio | 4.12 |
Interest Coverage | −11.26 |
Quick Ratio
TOI
Profitability
|
Metric
|
TOI
|
|---|---|
Return on Assets (Normalized) | −20.82% |
Return on Equity (Normalized) | −55.21% |
Return on Invested Capital (Normalized) | −20.50% |
Return on Assets
TOI
Medical Care Facilities Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
HCA
| HCA Healthcare Inc | Zsddlwkff | Crjzj | $83.1 Bil | |
FSNUY
| Fresenius SE & Co KGaA ADR | — | Ntkvsdf | $16.4 Bil | |
FSNUF
| Fresenius SE & Co KGaA | — | Wblyny | $16.4 Bil | |
BDUUY
| Bangkok Dusit Medical Services PCL ADR | — | Cpmg | $12.3 Bil | |
FMCQF
| Fresenius Medical Care AG | — | Gpmgzs | $11.9 Bil | |
FMS
| Fresenius Medical Care AG ADR | Dnp | Cyxfp | $11.9 Bil | |
DVA
| DaVita Inc | Bxjxgjzrs | Syckdqy | $11.7 Bil | |
UHS
| Universal Health Services Inc Class B | — | Xznbyc | $11.2 Bil | |
THC
| Tenet Healthcare Corp | Xghyyhcmx | Wls | $9.5 Bil | |
AMN
| AMN Healthcare Services Inc | Tnclydw | Gqjgpc | $2.2 Bil |